Cergentis
Menu

Breast and Ovarian Cancer

Research & Diagnostics

Breast and ovarian cancers are frequently caused by germ line and/or somatic mutations in BRCA genes. Cancers with BRCA pathway inactivation are sensitive to targeted treatment with PARP inhibitors, hence accurate and complete detection of BRCA mutations is very important as companion diagnostics. TLA enables broader and more complete sequencing of BRCA1 and 2 genes, which enables detection of all mutations, including intronic and promoter events and structural variation.

 

TLA empowers the detection of both single nucleotide variants and structural variants in any other genomic region that is (potentially) relevant for prognosis and/or therapy choice.

  • Application notes
  • Publications
  • Webinars
  • Application notes
  • Robust detection of structural variants and single nucleotide variants in FFPE
    Robust detection of structural variants and single nucleotide variants in FFPE
  • Publications
  • Spectrum of genetic variants of BRCA1 and BRCA2 in a German single center study

    Meisel C et al. (2017)                                                                                                            

    DKFZ, Medical Genetic Center Munich, National Center for Tumor Diseases (NCT), TU Dresden, University Kiel

  • Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer

    Ter Brugge P et al. (2016)                                                                                                            

    Bellvitge Biomedical Research Institute Barcelona, Curie Institute, ICREA, Institute of Cancer Research London, The Netherlands Cancer Institute, University of Barcelona & University Medical Center Utrecht

  • Sequencing Structural Variants in Cancer for Precision Therapeutics

    Macintyre G et al. (2016)                                                                                                            

    University of Cambridge & VU University Medical Center

  • Targeted Locus Amplification (TLA): A Novel Next Generation Sequencing (NGS) Technology to Detect New Molecular Markers and Monitoring Minimal Residual Disease (MRD) in Mantle Cell and Follicular Lymphoma

    Genuardi E et al. (2017)                                                                                                            

    A.O.U. Citta della Salute e della Scienza di Torino, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Cergentis, Clinica Humanitas/Gavazzeni, University of Modena e Reggio Emilia & University of Torino

  • Personalized Medicine in Lymphoma: Tailoring Treatment According to Minimal Residual Disease

    Dogliotti I & Ferrero S (2017)                                                                                                            

    A.O.U. Citta della Salute e della Scienza di Torino & University of Torino

  • Activating ESR1 Mutations Differentially Impact the Efficacy of ER Antagonists

    Toy W et al. (2016)                                                                                                                             

    AstraZeneca, Memorial Sloan Kettering Cancer Center, University of Chicago & University of Illinois at Urbana Champaign

  • Guidelines for cytogenetic investigations in tumours

    Hastings RJ et al. (2015)                                                                                                            

    Charles University Prague, CHUV, Great Ormond St Hospital, Gustave Roussy, Hospital del Mar, Institute of Genomic Medicine, Oslo University Hospital, Ospedale di Circolo-Polo Universitario, Our Lady's Children's Hospital, Oxford University Hospitals NHS Trust, Radboud University Medical Center, St James's Hospital, University of Cagliari, University of Groningen, University Hospital Ghent, UZ Leuven, VU University Medical Center

  • Targeted sequencing by proximity ligation for comprehensive variant detection and local haplotyping

    De Vree PJP et al.  (2014)                                                                                                                             

    Cergentis, Erasmus Medical Center, Ghent University, Hubrecht Institute-KNAW, Leiden University Medical Center, The Netherlands Cancer Institute, Radboud University Medical Center, University of Amsterdam, University of Groningen, University Medical Center Utrecht & VIB

  • Webinars
  • Applications and principles of TLA-based complete gene sequencing and haplotyping

     

  • Whole genome coverage plots generated with TLA and standard capture. The obtained sequencing coverage is much wider for proximity ligated samples than for standard targeting procedures, which enables the robust detection of structural variants.
  • BRCA1 coverage profiles generated with TLA and standard capture – in combination with TLA more complete coverage is obtained.
  • Whole genome coverage plots generated with TLA and standard capture. The obtained sequencing coverage is much wider for proximity ligated samples than for standard targeting procedures, which enables the robust detection of structural variants.
  • BRCA1 coverage profiles generated with TLA and standard capture – in combination with TLA more complete coverage is obtained.

TLA enables

  • Detection of all mutations in BRCA genes including small mutations and structural variation
  • Analysis on cells or FFPE
© 2012-2020 Cergentis B.V. All rights reserved.
For Research Use Only.Not for use in diagnostic procedures.